2248003-60-1Relevant articles and documents
C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER
-
, (2018/11/21)
The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their prepar
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors
Kettle, Jason G.,Anjum, Rana,Barry, Evan,Bhavsar, Deepa,Brown, Crystal,Boyd, Scott,Campbell, Andrew,Goldberg, Kristin,Grondine, Michael,Guichard, Sylvie,Hardy, Christopher J.,Hunt, Tom,Jones, Rhys D. O.,Li, Xiuwei,Moleva, Olga,Ogg, Derek,Overman, Ross C.,Packer, Martin J.,Pearson, Stuart,Schimpl, Marianne,Shao, Wenlin,Smith, Aaron,Smith, James M.,Stead, Darren,Stokes, Steve,Tucker, Michael,Ye, Yang
, p. 8797 - 8810 (2018/10/05)
While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to establish